1 active not recruiting, 1 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Nelum Corp: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. Gemcitabine (1000 mg/m2), Nab-paclitaxel (Abraxane), NLM-001 - Untreated, Advanced Pancreatic Cancer | Phase 2 | Not yet recruiting | Nelum Corp | 40 | 2026-07-15 | 2026-05-13 |
| Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer Gemcitabine, Nab paclitaxel, NLM-001 - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Nelum Corp | 28 | 2021-09-01 | 2024-12-30 |
Neoplasms (1) · Pancreatic Neoplasms (1)
Gemcitabine (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Taxes (1)
Spain (2)